secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2026-07-29T14:05:21+00:00
Accession:  0001104659-26-087891
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor's HOPE-3 Deramiocel data published in The Lancet; LVEF p-value revised to 0.09; FDA BIMO inspection cited
--------------------------------------------------------------------------------

- HOPE-3 Phase 3 results published in The Lancet; primary endpoint met: 54% slowing of upper limb decline (PUL 2.0, p=0.03).
- LVEF secondary endpoint p-value revised to 0.09 (1.8 ppt difference) from previously reported 0.04 (2.4 ppt) under updated statistical model.
- FDA BIMO inspection (July 6-20) resulted in Form 483 observation on SOPs, documentation, vendor oversight; company says data integrity unaffected.
- Deramiocel BLA under FDA review with PDUFA target action date of August 22, 2026.
- Pre-specified cardiomyopathy subgroup showed nominally significant LVEF benefit (p=0.02, 2.8 ppt difference).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000110465926087891/0001104659-26-087891-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000110465926087891/capr-20260729x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-087891

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer